银诺医药赴港上市:将人源长效GLP-1受体激动剂推进到注册审批

IPO早知道
04 Dec 2024

亚洲第一家、全球第三家。本文为IPO早知道原创作者|Stone Jin据IPO早知道消息,广州银诺医药集团股份有限公司(以下简称“银诺医药”)于2024年12月3日正式向港交所递交招股说明书,拟主板挂牌上市,中信证券和中金公司担任联席保荐人。成立于2014年的银诺医药一直致力于研究并开发治疗糖尿病和其他代谢性疾病的创新疗法。截至2024年11月24日,银诺医药已建立一条管线,包括1、依苏帕格鲁肽α...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10